Compare Sana Biotechnology Inc (SANA) vs Consumer Staples Select Sector SPDR Fund (XLP) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Sana Biotechnology Inc vs Consumer Staples Select Sector SPDR Fund — how do they compare? Sana Biotechnology Inc trades at $3.17 (market cap $873.84M), while Consumer Staples Select Sector SPDR Fund trades at $84.15. The key difference: Consumer Staples Select Sector SPDR Fund is trading nearer its 52-week high, Sana Biotechnology Inc nearer its low. Which is the better fit depends on your goals.
| SANA | XLP | |
|---|---|---|
Market Cap | $873.84M | — |
Sector | Health | — |
52-Week High | $5.92 | $90.00 |
52-Week Low | $2.68 | $75.61 |
Enterprise Value | $848.03M | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
SANA Biotechnology trades at $3.14, down 0.32% with bearish technical indicators despite strong analyst support. The company shows significant financial challenges with negative ROE of -147.41% and net income of -$244.17M for 2025, though cash burn improved from -$55M to -$12M in 2026. Recent positive developments include a Zacks upgrade to Buy and groundbreaking clinical data published in NEJM.
Investment outlook remains speculative with high execution risk given substantial losses, but strong analyst consensus (82% Buy ratings) reflects optimism about SANA's innovative cell therapy pipeline. Key risks include continued cash burn and clinical trial outcomes, while potential catalysts include successful product development in diabetes and CAR-T therapies.
XLP trades at $84.86, down 0.39% on the day, with a bullish technical signal supported by moving averages. The ETF maintains a 2.6% dividend yield and shows strength in defensive positioning amid market volatility. Analyst consensus is unanimously positive with 2 buy ratings and no hold or sell recommendations.
The consumer staples ETF offers defensive exposure during economic uncertainty, with technical indicators supporting near-term upside potential. Key risks include sector concentration and competition from broader alternatives. Current levels near pivot point resistance at $86 represent the immediate technical challenge.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Sana Biotechnology Inc
Sana Biotechnology Inc. is a clinical-stage biopharmaceutical company focused on creating and delivering engineered cells as medicines for patients. The company is developing cell therapies for various diseases, including oncology, diabetes, and central nervous system disorders. Sana's core strategy is built around two key technological platforms: in vivo gene delivery to repair cells inside the body and ex vivo cell engineering for therapeutic use.
Read more on SANA →About Consumer Staples Select Sector SPDR Fund
In seeking to track the performance of the index, the fund employs a replication strategy. It generally invests substantially all, but at least 95%, of its total assets in the securities comprising the index. The index includes companies that have been identified as Consumer Staples companies by the GICS®. It is non-diversified.
Read more on XLP →
